UBRELVY 100 MG Israel - engleză - Ministry of Health

ubrelvy 100 mg

abbvie biopharmaceuticals ltd, israel - ubrogepant as trihydrate - tablets - ubrogepant as trihydrate 100 mg - ubrelvy is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults.limitations of useubrelvy is not indicated for the preventive treatment of migraine.

UBRELVY 50 MG Israel - engleză - Ministry of Health

ubrelvy 50 mg

abbvie biopharmaceuticals ltd, israel - ubrogepant as trihydrate - tablets - ubrogepant as trihydrate 50 mg - ubrelvy is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults.limitations of useubrelvy is not indicated for the preventive treatment of migraine.

ZEMPLAR 1 MICROGRAM Israel - engleză - Ministry of Health

zemplar 1 microgram

abbvie biopharmaceuticals ltd, israel - paricalcitol - capsules soft - paricalcitol 1 mcg - paricalcitol - zemplar is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal insufficiency (chronic kidney disease stage 3 and 4 ) patients and chronic renal failure (chronic kidney disease stage 5) patients on haemodialysis or peritoneal dialysis.

ORILISSA150 MG Israel - engleză - Ministry of Health

orilissa150 mg

abbvie biopharmaceuticals ltd, israel - elagolix as sodium - film coated tablets - elagolix as sodium 150 mg - elagolix - orilissa is indicated for the management of moderate to severe pain associated with endometriosis.

ORILISSA 200 MG Israel - engleză - Ministry of Health

orilissa 200 mg

abbvie biopharmaceuticals ltd, israel - elagolix as sodium - film coated tablets - elagolix as sodium 200 mg - elagolix - orilissa is indicated for the management of moderate to severe pain associated with endometriosis.

SKYRIZI 600 MG Israel - engleză - Ministry of Health

skyrizi 600 mg

abbvie biopharmaceuticals ltd, israel - risankizumab - concentrate for solution for infusion - risankizumab 60 mg/ml - risankizumab - skyrizi is indicated for the treatment of patients 16 years and older with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy, or if such therapies are not advisable.

SKYRIZI 360 MG Israel - engleză - Ministry of Health

skyrizi 360 mg

abbvie biopharmaceuticals ltd, israel - risankizumab - solution for injection - risankizumab 150 mg/ml - risankizumab - skyrizi is indicated for the treatment of patients 16 years and older with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy, or if such therapies are not advisable.

VENCLEXTA 10 MG TABLETS Israel - engleză - Ministry of Health

venclexta 10 mg tablets

abbvie biopharmaceuticals ltd, israel - venetoclax - film coated tablets - venetoclax 10 mg - venetoclax - chronic lymphocytic leukemia/small lymphocytic lymphomavenclexta in combination with rituximab or as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll), who have received at least one prior therapy.venclexta in combination with obinutuzumab is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll).acute myeloid leukemiavenclexta in combination with a hypomethylating agent or in combination with low dose cytarabine is indicated for newly diagnosed patients with acute myeloid leukemia (aml) who are ineligible for intensive chemotherapy.

VENCLEXTA 100 MG TABLETS Israel - engleză - Ministry of Health

venclexta 100 mg tablets

abbvie biopharmaceuticals ltd, israel - venetoclax - film coated tablets - venetoclax 100 mg - venetoclax - chronic lymphocytic leukemia/small lymphocytic lymphomavenclexta in combination with rituximab or as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll), who have received at least one prior therapy.venclexta in combination with obinutuzumab is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll).acute myeloid leukemiavenclexta in combination with a hypomethylating agent or in combination with low dose cytarabine is indicated for newly diagnosed patients with acute myeloid leukemia (aml) who are ineligible for intensive chemotherapy.

VENCLEXTA 50 MG TABLETS Israel - engleză - Ministry of Health

venclexta 50 mg tablets

abbvie biopharmaceuticals ltd, israel - venetoclax - film coated tablets - venetoclax 50 mg - venetoclax - chronic lymphocytic leukemia/small lymphocytic lymphomavenclexta in combination with rituximab or as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll), who have received at least one prior therapy.venclexta in combination with obinutuzumab is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll).acute myeloid leukemiavenclexta in combination with a hypomethylating agent or in combination with low dose cytarabine is indicated for newly diagnosed patients with acute myeloid leukemia (aml) who are ineligible for intensive chemotherapy.